NorthWest Biotherapeutics Inc (NWBO)

[LearningEveryTrade]

Primary Endpoint is OS.
https://clinicaltrials.gov/ct2/show/NCT00045968?term=dcvax&draw=2&rank=4

Outcome Measures
Go to sections
Primary Outcome Measures :
The primary objective of this study is to compare overall survival (OS) between patients randomized to DCVax-L and control patients from comparable, contemporaneous trials who received standard of care therapy only, in newly diagnosed glioblastoma. [ Time Frame: Until death ]

Secondary Outcome Measures :
The first secondary objective is to compare overall survival (OS) between patients randomized to placebo who received DCVax-L treatment following disease recurrence, and control patients from comparable, contemporaneous clinical trials, in recurrent GBM. [ Time Frame: Until death ]